efalizumab


Also found in: Wikipedia.

efalizumab

a rarely used immunosuppressant.
indications This drug is used in adults 18 years of age and older to treat moderate to severe plaque psoriasis.

efalizumab

A recombinant, humanized monoclonal antibody to CD11 a used to treat moderate to severe PSORIASIS.
References in periodicals archive ?
The biologic efalizumab prevents the migration of activated T-cells into the skin from the lymph nodes.
Unlike alefacept and efalizumab, which interfere with T-cell activation, etanercept binds to tumor necrosis factor (TNF) to inhibit the inflammation associated with psoriasis.
Gottlieb, who has received research funding from the makers of etanercept, infliximab, adalimumab, efalizumab, and alefacept.
This shows that efalizumab "doesn't poop out" during long-term administration, she said.
Panelists concluded that the safety and efficacy of the approved biologic therapies for psoriasis--alefacept, efalizumab, and etanercept--have been far better documented in large, well-designed clinical trials than have any of the older therapeutic alternatives.
Pooled data from company trials of efalizumab show no safety concerns with up to 2 years of continuous use, the longest anyone has taken the drug.
The biggest drawback is that both drugs can result in relapse on withdrawal, and efalizumab can elicit a strong rebound reaction in up to 14% of patients, especially nonresponders.
The other biologics fall far behind this efficacy level: PASI 75 improvement by 3 months in 21% for alefacept, 28% for efalizumab, 34% for etanercept 25 mg biweekly, and 49% for etanercept 50 mg biweekly.
The biologics approved for treating chronic, moderate to severe plaque psoriasis now include alefacept, etanercept, and efalizumab (Raptiva).
These drugs include etanercept, infliximab, adalimumab, alefacept, and efalizumab.
CHICAGO -- Evidence is mounting that biologic therapies such as alefacept and efalizumab can successfully treat palmoplantar pustular psoriasis.
These occurred most often within 48 hours of efalizumab injection, and consisted primarily of headache, fever, chills, nausea, pharyngitis, and a flulike syndrome.